Behringwerke Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Novartis Vaccines & Diagnostics, Gmbh

Dade Behring Marburg Gmbh

Mathias Fibi

Werner Stuber

Peter Hermentin

Gerd Zettlmeissl

Michael Broker

Hans Kupper

Werner Stüber

The invention provides a syringe accessory device for adjustment of a predefined partial syringe dosage comprises a recess () for receiving a syringe body (). Additionally, within a single portion () a slot () is located. Within the slot () a syringe flange () or finger grip can be held. To obtain a predefined dosage of liquid within the chamber of the syringe body (), a plunger () is pressed in the chamber () in the direction of the arrow () until the plunger head () contacts a stopping means () whereby the stopping means is performed by a stopping surface () of the single portion (). The invention further provides a kit comprising said syringe accessory device and its use for adjusting defined liquid dosages in syringes.

Syringe accessory device

Erythropoietin (EPO) peptides and the use thereof for preparing epitope-specific anti-EPO antibodies are described. Also described are corresponding anti-EPO antibodies which take the form of polyclonal antibodies (antisera) or of monoclonal antibodies. These antibodies are suitable for purifying EPO, EPO derivatives or EPO peptides. The epitope-specific anti-EPO antibodies according to the invention can also be used for the detection of EPO and, in particular, for the epitope-specific detection of EPO. Additionally described are anti-idiotype antibodies which imitate a receptor region of EPO. Finally, pharmaceuticals which contain the EPO peptides, anti-EPO antibodies or anti-idiotype antibodies, and diagnostic aids for the detection of EPO or of anti-EPO antibodies, are described.

Erythropoietin (EPO) peptides and antibodies directed against these

A method for the production of a polypeptide, the method comprising culturing, under conditions which allow for the expression of DNA encoding SEQ ID NO:2 in an eukaryotic host cell, wherein the DNA is in vector pPHOEBE-40-7, and optionally isolating the polypeptide from the culture, is described. A polypeptide obtained by such method and a pharmaceutical composition comprising the polypeptide also are described. A composition for diagnosing anemia comprising such polypeptide and a method of treating anemia caused by lack of erythropoietin also are described.

Recombinant human erythropoietin with advantageous glycosylation profile

The invention relates to muteins of human erythropoietin (EPO) in the carboxyl terminal region which are prepared by means of recombinant DNA techniques. These mutants have advantageous properties in comparison with human wild-type EPO.

Muteins of human erythropoietin, the preparation thereof and the use

A method for degrading nucleic acids in a waste fermentation solution is disclosed. The method comprises exposing the waste solution to RNases and/or DNases released by autolysis of and/or secreted from Paecilomyces lilaninus which are present in or added to the waste solution. The fermentation of the microorganism occurs under sterile conditions. The microorganism can be transformed with nuclease-encoding genes and added to the waste solution before fermentation. The preferred strain of Paecilomyces lilacinus is DSM 5650.

Method for degrading nucleic acids in waste fermentation solutions with

Erythropoietin (EPO) peptides and the use thereof for preparing epitope-specific anti-EPO antibodies are described. Also described are corresponding anti-EPO antibodies which take the form of polyclonal antibodies (antisera) or of monoclonal antibodies. These antibodies are suitable for purifying EPO, EPO derivatives or EPO peptides. The epitope-specific anti-EPO antibodies according to the invention can also be used for the detection of EPO and, in particular, for the epitope-specific detection of EPO. Additionally described are anti-idiotype antibodies which imitate a receptor region of EPO. Finally, pharmaceuticals which contain the said EPO peptides, anti-EPO antibodies or anti-idiotype antibodies, and diagnostic aids for the detection of EPO or of anti-EPO antibodies, are described.

Growing community of inventors

Marburg, Germany

Mathias Fibi